Mevion's Compact Proton System Clears EU, Set to Disrupt Cancer Care

LITTLETON, MA – February 25, 2026 – Mevion Medical Systems has secured a pivotal regulatory approval that could significantly alter the landscape of advanced cancer treatment in Europe. The company announced its MEVION S250-FIT Proton Therapy System has received CE Marking, clearing the path for its sale and clinical use across the European Union.

This milestone follows the system's U.S. FDA 510(k) clearance granted in September 2025, establishing a global footprint for a technology designed to solve the biggest challenge in proton therapy: accessibility. Unlike conventional proton systems that require the construction of massive, multi-story concrete bunkers, the S250-FIT is engineered to be installed within the confines of a standard radiation therapy vault, a feature that promises to democratize access to one of oncology's most precise tools.

A Paradigm Shift in Cancer Center Construction

For decades, the immense cost and logistical complexity of building a proton therapy center have limited its availability to only a handful of elite institutions. Traditional multi-room facilities can cost upwards of $250 million and take years to construct, putting them far out of reach for most hospitals. Mevion aims to shatter this paradigm.

The core innovation of the MEVION S250-FIT is its ability to be retrofitted into existing infrastructure. This claim is already being put to the test. At Stanford Health Care in California, construction is underway to install the system in a conventional linear accelerator (LINAC) vault, a first for the industry. This approach drastically reduces the upfront capital investment and shortens the project timeline from years to months, enabling hospitals to reallocate resources toward patient care rather than massive construction projects.

This design philosophy extends to the system's operational footprint. By integrating an upright patient positioning system from partner Leo Cancer Care, the S250-FIT eliminates the need for a colossal, 360-degree rotating gantry. Instead, the patient is rotated with precision, a change that dramatically reduces the required room size and shielding complexity. For European health systems facing spatial and financial constraints, this compact design presents a viable pathway to offering proton therapy without the need for a new building.

Advanced Clinical Power in a Compact Package

While its reduced size is a major selling point, the MEVION S250-FIT does not compromise on clinical capability. The system is built around Mevion's HYPERSCAN® pencil beam scanning (PBS) platform, a technology that delivers Intensity Modulated Proton Therapy (IMPT) with exceptional precision. HYPERSCAN produces a micro-beam with a sharper dose fall-off at the edge of a tumor compared to many competing systems, which is critical for sparing adjacent healthy tissue and sensitive organs.

The platform's speed is another key clinical advantage. With energy layers that can be switched in as little as 50 milliseconds, clinicians can perform rapid volumetric scanning. This allows for the treatment of tumors affected by organ motion, such as in the lung, within a single breath-hold, minimizing inaccuracies caused by patient breathing. This precision is further enhanced by the Adaptive Aperture®, a proton-specific multi-leaf collimator that shapes the beam layer by layer to conform tightly to complex tumor shapes.

The system is also designed to support emerging treatment techniques like DirectARC™, a rotational proton arc therapy that promises to deliver treatments with the speed and efficiency of conventional VMAT while retaining the tissue-sparing benefits of protons. An integrated large-bore diagnostic CT scanner enables advanced image-guided radiation therapy (IGRT) and adaptive workflows, allowing clinicians to adjust treatments based on daily changes in a patient's anatomy.

Navigating a Challenging Regulatory and Competitive Landscape

Securing CE Marking under the European Union's Regulation (EU) 2017/745 (EU MDR) is a significant achievement in its own right. The EU MDR, which replaced the former Medical Device Directive (MDD), imposes far more stringent requirements for clinical evidence, post-market surveillance, and overall product safety. Successfully navigating this rigorous process signals to the market that the S250-FIT has met the highest contemporary standards for medical devices.

With this approval, Mevion enters a competitive but growing European proton therapy market, currently valued at over $555 billion. The company will now compete more directly with established industry giants like Varian, Hitachi, and IBA, all of which have a presence in Europe. However, Mevion's unique value proposition—offering a full-featured proton system at a fraction of the traditional infrastructure cost—could be a powerful differentiator. As of 2020, Europe had just over 30 operational proton centers, leaving a vast, underserved market of hospitals that recognize the clinical benefits of proton therapy but have been deterred by the financial and logistical hurdles.

Building on Global Momentum

The European launch builds on strong momentum in the United States. Mevion has already signed contracts for the S250-FIT platform with nine institutions globally, including prominent U.S. centers such as Stanford Health Care, BayCare Health System in Florida, Atlantic Health System in New Jersey, the University of Nebraska Medical Center, and UNC Health. These partnerships with leading academic and community hospitals validate the demand for a more accessible proton therapy solution.

The technology is also an evolution of the company's proven MEVION S250i® platform, which has been in clinical operation at the ZON-PTC at Maastro Clinic in the Netherlands since 2018, giving European customers confidence in the underlying accelerator technology.

"For European health systems that have long recognized the clinical benefits of proton therapy but faced significant infrastructure and financial barriers, the S250-FIT offers a fundamentally new approach, one that brings high-quality proton therapy directly into existing treatment environments," said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems, in a recent statement. "This is a defining moment for accessible cancer care in Europe and beyond."

By removing the most significant barriers to adoption, the MEVION S250-FIT is poised to accelerate the expansion of proton therapy, potentially making this superior standard of cancer care available to thousands more patients across Europe in the coming years.